Scholar Rock Holding (SRRK) Income from Non-Controlling Interests (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Income from Non-Controlling Interests came in at -$71000.0 in Q1 2026, down 129.03% year-on-year from $244555.6 in Q1 2025, and down 238.1% quarter-over-quarter from -$21000.0 in Q4 2025.
Scholar Rock Holding (SRRK) Income from Non-Controlling Interests (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at -$71000.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 129.03% year-over-year to -$71000.0 in Q1 2026; TTM through Mar 2026 was -$104000.0, a 158.1% decrease from a year earlier, with the FY2025 full-year figure at -$64000.0, down 194.12% from the prior year.
- Income from Non-Controlling Interests retreated to -$71000.0 in Q1 2026 per SRRK's latest filing, from -$21000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $555000.0 in Q1 2023 and bottomed at -$857000.0 in Q3 2022.
- The 5-year median for Income from Non-Controlling Interests is $32000.0 (2024), against an average of $3529.4.
- Biggest YoY gain for Income from Non-Controlling Interests was 621.43% in 2022; the steepest drop was 9422.22% in 2022.
- Year by year, Income from Non-Controlling Interests stood at $52000.0 in 2022, then jumped by 121.15% to $115000.0 in 2023, then tumbled by 72.17% to $32000.0 in 2024, then sank by 165.62% to -$21000.0 in 2025, then slumped by 238.1% to -$71000.0 in 2026.
- Per Business Quant, the three latest SRRK Income from Non-Controlling Interests figures stand at -$71000.0 (Q1 2026), -$21000.0 (Q4 2025), and $59000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | - |
| 10 | Scholar Rock Holding | 6.27 Bn | 6.27 Bn | - | -71,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -71,000.00 |
| Dec 31, 2025 | -21,000.00 |
| Sep 30, 2025 | 59,000.00 |
| Jun 30, 2025 | -71,000.00 |
| Mar 31, 2025 | -31,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | 182,000.00 |
| Jun 30, 2024 | -4,000.00 |
| Mar 31, 2024 | -142,000.00 |
| Dec 31, 2023 | 115,000.00 |
| Sep 30, 2023 | 40,000.00 |
| Jun 30, 2023 | 266,000.00 |
| Mar 31, 2023 | 555,000.00 |
| Dec 31, 2022 | 52,000.00 |
| Sep 30, 2022 | -857,000.00 |
| Jun 30, 2022 | 73,000.00 |
| Mar 31, 2022 | -117,000.00 |
| Dec 31, 2021 | -35,000.00 |
| Sep 30, 2021 | -9,000.00 |
| Jun 30, 2021 | -14,000.00 |